The Company

Targeted Therapeutics, LLC is a preclinical biopharmaceutical company developing novel therapeutics that target cancer cells by disrupting multiple signaling pathways that cancer cells depend on for survival. The Company’s TT-101 combination drug induces mitosis-related death in proliferating cancer cells and blocks mitotic entry in healthy cells leaving them unaffected.

Targeted Therapeutics has validated the performance of TT-101 in preclinical studies with pancreatic cancer and NSCLC cells in vitro and in mice. The Company is conducting additional preclinical studies including: an animal toxicology study to establish safe dosage for human testing; a drug efficacy study in mice to determine cancer types that are most sensitive to TT-101 to provide a basis for selecting clinical trial patients; and a pharmacodynamics study to determine the bioavailability and metabolism of TT-101.

Management

Bill Ponton, MBA
CEO

Bill Ponton is CEO of Targeted Therapeutics, LLC. Bill has managed and invested in several early-stage biotech companies. Prior to his involvement in biotech, he managed and invested in several successful technology startups in the digital video space. Earlier in his career, he served on the staff of Princeton University in the Plasma Physics Lab. Mr. Ponton holds an MBA from NYU Stern School of Business and a BS degree in Electrical Engineering from Rutgers University.